| Date | Title | Description |
| 05.05.2024 | Experts Predict AI Hallucinations Could Soon Lead to Development of Life-Saving Drugs | John Lopez, Tech Times 05 May 2024, 12:05 pm
In a recent report by CNBC, experts reveal how artificial intelligence (AI), particularly generative AI, is poised to transform the field of drug discovery.
The report unveiled the surprising suc... |
| 18.03.2024 | AI drug breakthrough possible for China | Ren Feng, co-CEO of Insilico Medicine, an AI-driven new drug discovery company. [Photo provided to chinadaily.com.cn]
China is capable of a breakthrough in artificial intelligence-backed drug discovery and able to catch up with the top leve... |
| 13.03.2024 | Novel Molecules From Generative AI to Phase II: First Novel TNIK Inhibitors for Fibrotic Diseases Discovered and Designed Using Generative AI | A study published in Nature Biotechnology presents the entire journey of INS018_055, from AI algorithms to Phase II clinical trials for the first time.
Raw data from 13 preclinical experiments and 3 clinical trials referenced in this study ... |
| 13.03.2024 | Первый в мире препарат для лечения заболевания лёгких, разработанный ИИ, проходит клинические испытания в Китае и США... | Экспериментальный препарат, разработанный с помощью искусственного интеллекта (ИИ) для борьбы с агрессивным и часто смертельным заболеванием лёгких, вступил во вторую фазу клинических испытаний в Китае и США. Как сообщает компания Insilico ... |
| 08.03.2024 | Insilico Medicine unveils first AI-generated and AI-discovered drug in new paper | Join leaders in Boston on March 27 for an exclusive night of networking, insights, and conversation. Request an invite here.
Insilico Medicine, the Hong Kong and New York-based biotech startup that has raised over $400 million to connect bi... |
| 20.02.2024 | Quantum-Enhanced Generative AI Generates Viable Cancer Drug Candidates | The research demonstrates a breakthrough in applying quantum-enhanced generative AI to drug discovery using today’s quantum devices
Zapata Computing, Inc,, the Industrial Generative AI company, announced that its scientists, in collaboratio... |
| 15.02.2024 | Insilico’s Potential Best-in-Class AI Drug for Sought-After Cancer Target | What You Should Know:
InSilico Medicine, a clinical-stage company utilizing generative artificial intelligence (AI) for drug discovery, reveals the development of an orally bioavailable preclinical candidate compound. This compound targets ... |
| 05.01.2024 | Menarini Group and Insilico Medicine Enter Global Exclusive License Agreement for Novel KAT6 Inhibitor for Potential Breast Cancer Treatment and Other Oncology Indications | KAT6 is an emerging target in hormone sensitive breast tumors and other cancers. Overexpression of KAT6A/B correlates with poor clinical outcomes in patients with ER+/HER2- breast cancer – the most common subtype.
The molecule has demonstra... |
| 26.12.2023 | Shinobi announced their $51M Series A funding | Shinobi Therapeutics, the biotechnology company developing a new class of immune evasive iPS-T cell therapies, announced their launch and $51M Series A funding.
Shinobi has created a new allogeneic CD8αβ iPS-T cell platform that demonstrate... |
| 19.12.2023 | AI-Generated Drug Candidates Are Here, But Clinical Trial Wins Need More Time | The numbers in drug discovery are daunting. Identifying a molecule with therapeutic promise and advancing it through preclinical and clinical development can take more than a decade at costs topping $2 billion, according to pharmaceutical i... |
| 19.12.2023 | Aramco unit injects $14m into China-based tumor detection startup | InvestmentsNews
Lokesh Choudhary · 27 Dec 2023 · 2 min readAramco unit injects $14m into China-based tumor detection startup
Photo credit: Shutterstock
The Asian startup scene has seen a recent boom in investments from the Middle East. Cisp... |
| 05.12.2023 | Insilico Medicine Announces First-in-Human Study for Orally PHD Inhibitor ISM5411 for Inflammatory Bowel Disease (IBD) | ISM5411 is an oral, PHD-specific inhibitor that facilitates the treatment of IBD by inducing the expression of gut barrier protective genes.
ISM5411 is Insilico Medicine's fifth AI-driven drug program to enter clinical trials, with the firs... |
| 16.11.2023 | Eight Roads HiBob Young Generation in Tech Report | For the second year running, we've launched 'The Young Generation in Tech' report together with our portfolio company HiBob - the global HR tech platform.
Attracting and retaining young talent is vital to European tech. We surveyed 2,000 20... |
| 13.09.2023 | Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor | — ISM3091 is a highly selective, orally bioavailable small molecule inhibitor of USP1
identified through Insilico Medicine's artificial intelligence (AI) platform,
with potent activity in BRCA-mutated tumor models —
— In May 2023, the U.S. ... |
| 03.08.2023 | Insilico Medicine’s generative AI tool inClinico’s high accuracy in predicting clinical trial outcomes | Head over to our on-demand library to view sessions from VB Transform 2023. Register Here
Insilico Medicine, a clinical-stage AI drug-discovery company, announced a groundbreaking medical milestone: It successfully predicted Phase II to Pha... |
| 31.07.2023 | 4 Ways Biopharma Is Applying AI/ML to Improve Drug Development Outcomes | Healthcare innovation in drug development intersects with a few critical trends: the rise of artificial intelligence (AI) applications in healthcare—particularly machine learning (ML) and predictive analytics; the need to reduce the costs a... |
| 22.07.2023 | Insilico Medicine Nominates Preclinical Candidate of Inhalation Solution for ISM001-055, the First Generative AI IPF Drug | Insilico Medicine merges nebulizer device with AI-driven drug discovery;
Potential advantages for the inhalation solution include a smaller effective dose, larger safety window and reduced side effects;
As demonstrated in preclinical studie... |
| 12.07.2023 | Insilico Medicine Launches First-in-Human Trial for AI-Discovered IBD Drug | What You Should Know:
Insilico Medicine (“Insilico”), a generative artificial intelligence (AI)-driven clinical-stage biotechnology company, today announced that the company has initiated the first-in-human study for ISM5411, a potentially ... |
| 30.06.2023 | Стартап Insilico Medicine проведёт на людях первое испытание сгенерированного ИИ препарата | Биотехнологический стартап Insilico Medicine из Гонконга, который основал аспирант МГУ, кандидат физико-математических наук Александр Жаворонков, испытает на людях препарат INS018_055 для лечения фиброза, специфической разновидности пневмон... |
| 29.06.2023 | Qiming-Backed AI Drug Discovery Startup Insilico Medicine Files For Hong Kong IPO | getty |
| 29.06.2023 | First-Fully AI-Generated Drug to Reach Human Clinical Trials This Week | Joseph Henry, Tech Times 29 June 2023, 04:06 pm
Insilico Medicine, a well-funded biotech startup based in Hong Kong, has made a groundbreaking leap in the pharmaceutical industry by developing the first drug entirely generated by artificial... |
| 27.06.2023 | First Drug Discovered and Designed with Generative AI Enters Phase II Trials, with First Patients Dosed | After completing the Phase 0 and Phase I human safety studies, INS018_055, Insilico's AI-discovered and AI-generated drug, has entered multi-regional Phase II clinical trials in the U.S and China.
The first human patients were dosed with th... |
| 22.06.2023 | Revolutionizing Drug Discovery: AI’s Role in Accelerating Breakthrough Treatments | In the intricate battle against diseases, finding effective solutions has always been a complex endeavor. The key lies in identifying the disrupted biological processes, locating the precise targets, and introducing molecules that can recti... |
| 21.06.2023 | Sanofi Goes All-In On AI | Chief Executive Officer of French pharmaceutical giant Sanofi, Paul Hudson, Paris, September 8, ... [+] 2021. (Photo by JOEL SAGET / AFP) (Photo by JOEL SAGET/AFP via Getty Images)AFP via Getty Images |
| 17.05.2023 | Insilico Medicine Successfully Explores the Advantages of Quantum Generative Adversarial Networks in Generative Chemistry | NEW YORK, May 17, 2023 /PRNewswire/ -- Insilico Medicine, a clinical stage generative artificial intelligence (AI)-driven drug discovery company, today announced that it groundbreakingly combines two rapidly developing technologies, quantum... |
| 13.05.2023 | UAE Biotech Insilico Medicine Offers Disease Modeling and Target Identification Course Using AI | Insilico Medicine, a generative artificial intelligence (AI)-driven drug discovery company, announced that it is releasing a course on Disease Modeling and Target Identification, available for free. Through seven lectures, the course guides... |
| 14.04.2023 | Daily AI Roundup: Biggest Machine Learning, Robotic And Automation Updates 14th April 2023 | This is our AI Daily Roundup . We are covering the top updates from around the world. The updates will feature state-of-the-art capabilities in artificial intelligence (AI), Machine Learning, Robotic Process Automation, Fintech, and human-s... |
| 13.04.2023 | Insilico Medicine Successfully Discovered Potent, Selective, and Orally Bioavailable Small Molecule Inhibitor of CDK8 Using Generative AI | Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, announced that it has successfully discovered a potent, selective, and orally bioavailable small molecule inhibitor of C... |
| 10.03.2023 | Tweekly. Выпуск 160. Бессмертие как сервис | Что сейчас растёт и как это применить
1. Бессмертие как сервис (IaaS). То, чего все хотят и боятся одновременно.
2. Цифровые клоны городов и производств — быстрая проверка «капиталоемких» гипотез. Следующий шаг - проверка жизнеспособности п... |
| 09.02.2023 | Insilico Medicine Receives FDA Orphan Drug Designation for Generative AI Discovered and Designed Drug for Idiopathic Pulmonary Fibrosis | Insilico Medicine (“Insilico”), a clinical-stage end-to-end generative artificial intelligence (AI)-driven drug discovery company, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to INS018_055 ... |
| 10.01.2023 | Insilico Medicine Announces Positive Topline Results of the New Zealand Phase I Trial of INS018_055, an AI-Designed Drug for an AI-Discovered Target | NEW YORK and HONG KONG, Jan. 10, 2023 /PRNewswire/ -- Insilico Medicine, a clinical stage artificial intelligence (AI)-driven drug R&D company, today announces positive topline results of safety, tolerability, and pharmacokinetics (PK) ... |
| 28.12.2022 | Insilico Medicine Nominates Preclinical Candidate Targeting KAT6A for ER+/HER2- Breast Cancer Therapy with End-to-End AI Engine | Insilico Medicine (“Insilico”), a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, announced that the company’s drug discovery team has nominated a preclinical candidate targeting KAT6A for ER+/HER2- bre... |
| 21.12.2022 | AI In Big Pharma: The First Antibody Designed Using AI In The Clinic | Terry Baker (right) and Jiye Shi were appointed UCB Fellows for their contributions to the design of ... [+] Bimekizumab Dr. Jiye Shi |
| 08.11.2022 | Insilico Medicine Signs Strategic Research Collaboration with Sanofi worth up to $1.2 Billion | Agreement includes aggregate upfront and target nomination fees of up to $21.5 million for up to 6 targets, and additional R&D and sales milestones plus tier-based mid-single- to low double-digit royalties.
New York , Nov. 8, 2022 /PRNe... |
| 07.09.2022 | Arpeggio Biosciences rakes in $17M to measure the transcriptome | How can drug developers design therapies around cellular networks rather than a single target?
That is the question Arpeggio Biosciences is seeking to answer — and with a new influx of funds. The Boulder, Colorado-based startup announced th... |
| 05.09.2022 | What is reinforcement learning? How AI trains itself | Were you unable to attend Transform 2022? Check out all of the summit sessions in our on-demand library now! Watch here.
Table of contents
What are some useful open-source options for reinforcement learning?
How do major providers handle re... |
| 11.08.2022 | Insilico Medicine Raises Funding From Prosperity7 Ventures; Brings Total Series D to $95M | Insilico Medicine, a New York-based clinical stage end-to-end artificial intelligence (AI)-driven drug discovery company, closed its Series D2 round, which brought total funding raised in Series D funding to $95M.
The Series D2 round was le... |
| 29.06.2022 | A Week At The Most Secretive Conference On Aging | Gordon Research Conference (GRC) Systems Aging 2022. Row 1: Vera Gorbunova, Cavin Ward-Caviness, ... [+] Samuel Beck, Sruthi Sivakumar, Vittorio Sebastiano, Steve Horvath, Vadim Gladyshev, Morgan Levine, Daniel Promislow, Brianah McCoy, Ric... |
| 07.06.2022 | How air taxi unicorn Volocopter plans to fund its 2024 service debut | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox.
The year is 2024, and you have just deplaned your flight in Rome. It seems like a great time to c... |
| 07.06.2022 | AI-Powered Hong Kong Biotech Startup Raises $60 Million From Top VCs Including B Capital, Qiming | Getty |
| 06.06.2022 | Insilico Medicine Raises $60M, Launches AI-powered Drug Discovery Robotics Laboratory | What You Should Know:
– Insilico Medicine, an NYC-based clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company raises $60 million in Series D financing from a syndicate of global investors with expertise in inv... |
| 06.06.2022 | Insilico gases up with $60M series D as the race to be the 'Formula One for Big Pharma' continues | Insilico has wrapped up a $60 million series D, adding additional fuel to its AI-driven drug discovery hot rod as the race to become the industry leader in predictive medicine heats up.
The latest fundraising round, which follows a $255 mil... |
| 06.06.2022 | Aledade scores $123M for value-based care and more digital health fundings | Photo: 10'000 Hours/Getty Images |
| 06.06.2022 | Hong Kong’s AI drug discovery firm Insilico closes $60M Series D | Insilico Medicine, a Hong Kong-based company that has been using artificial intelligence to discover new drugs since 2014, has completed a fresh round of funding.
It’s a sign that certain investors are continuing to bet on emerging biotechn... |
| 02.03.2022 | Alliance for Artificial Intelligence in Healthcare Elects New Board Leadership for 2022 | “AI will continue to have a demonstrable impact on human health. Having spent the last three years ideating with my fellow charter members to establish AAIH, I’m honored to take the reins and thrilled I get to engage with an incredible team... |
| 25.02.2022 | First Wholly AI-Developed Drug Enters Phase 1 Trials | Drug development is increasingly turning to AI Gavriil Grigorov/TASS |
| 01.12.2021 | Insilico Medicine Initiates First-in-Human Study of ISM001-055, a Novel Drug Discovered Using Insilico's Proprietary End-to-end Artificial Intelligence Platform | NEW YORK and HONG KONG, Dec. 1, 2021 /PRNewswire/ -- Insilico Medicine, an end-to-end artificial intelligence (AI)-driven drug discovery company, today announced that the first healthy volunteer has been dosed in a first-in-human microdose ... |
| 23.09.2021 | Insilico Medicine Appoints Nirav Jhaveri as Chief Financial Officer | NEW YORK and HONG KONG, Sept. 23, 2021 /PRNewswire/ -- Insilico Medicine, an end-to-end artificial intelligence (AI)-powered drug discovery company, today announced the appointment of Nirav Jhaveri as Chief Financial Officer (CFO) to overse... |
| 02.09.2021 | Insilico Medicine Appoints the Former Chief Medical Officer of Schering Plough, Dr. Robert Spiegel, MD, FACP, as acting Chief Medical Officer (CMO) to Oversee the Clinical Translation of its Preclinic... | SHANGHAI and NEW YORK, Sept. 2, 2021 /PRNewswire/ -- Insilico Medicine, an end-to-end AI-powered drug discovery company, today announced the appointment of Robert Spiegel as acting CMO to oversee the clinical translation of its preclinical ... |
| 02.09.2021 | Insilico Medicine Appoints the Former Chief Medical Officer of Schering Plough, Dr. Robert Spiegel, MD, FACP, as acting Chief Medical Officer (CMO) to Oversee the Clinical Translation of its Preclinic... | SHANGHAI and NEW YORK, Sept. 2, 2021 /CNW/ -- Insilico Medicine, an end-to-end AI-powered drug discovery company, today announced the appointment of Robert Spiegel as acting CMO to oversee the clinical translation of its preclinical pipelin... |
| 02.09.2021 | Insilico Medicine Appoints the Former Chief Medical Officer of Schering Plough, Dr. Robert Spiegel, MD, FACP, as acting Chief Medical Officer (CMO) to Oversee the Clinical Translation of its Preclinic... | SHANGHAI and NEW YORK, Sept. 2, 2021 /PRNewswire/ -- Insilico Medicine, an end-to-end AI-powered drug discovery company, today announced the appointment of Robert Spiegel as acting CMO to oversee the clinical translation of its preclinical ... |
| 01.09.2021 | Insilico Medicine Collaborates with Gray Matter to Fight Age-related Cognitive Decline | HONG KONG, Sept. 1, 2021 /PRNewswire/ -- Insilico Medicine is pleased to announce an R&D collaboration with Gray Matter, a longevity biotechnology company focused on peptide-based interventions against cognitive decline, age-related CNS... |
| 27.08.2021 | Insilico Medicine and 4B Technologies Announce Strategic Collaboration in Advancing Novel Drug Discovery for Neurodegenerative Diseases | SHANGHAI, Aug. 27, 2021 /PRNewswire/ -- Insilico Medicine ("Insilico"), an end-to-end artificial intelligence (AI)-driven drug discovery company, and 4B Technologies Co., Ltd. ("4B Technologies"), a leading end-to-end in... |
| 20.08.2021 | Insilico Medicine Collaborates with BioNova to Develop Small Molecule Drugs for Hematologic Malignancies | SHANGHAI, Aug. 20, 2021 /PRNewswire/ -- Insilico Medicine ("Insilico"), an end-to-end artificial intelligence-driven drug discovery company, and BioNova Pharmaceuticals (Shanghai) Ltd. ("BioNova"), a clinical-stage bioph... |
| 11.08.2021 | The Former Director of the Center for Drug Evaluation and Research at FDA and R&D Leader at Amgen, Steven Galson Joins Insilico Medicine as Independent Director | HONG KONG, Aug. 11, 2021 /PRNewswire/ -- Insilico Medicine, a global leader in end-to-end AI-powered drug discovery, today announced the appointment of Steven Galson, MD, MPH as the independent member of the board of directors.
"Succes... |
| 09.08.2021 | Arvinas : Insilico Medicine Announces an AI-driven PROTAC R&D Collaboration with Arvinas | HONG KONG, Aug. 9, 2021 /CNW/ -- Insilico Medicine is proud to announce an R&D collaboration with Arvinas (NASDAQ: ARVN). This strategic partnership will involve Insilico Medicine's AI-augmented platforms and close cooperation between A... |
| 09.08.2021 | Insilico Medicine Announces an AI-driven PROTAC R&D Collaboration with Arvinas | HONG KONG, Aug. 9, 2021 /PRNewswire/ -- Insilico Medicine is proud to announce an R&D collaboration with Arvinas (NASDAQ: ARVN). This strategic partnership will involve Insilico Medicine's AI-augmented platforms and close cooperation be... |
| 05.08.2021 | Insilico Medicine and Usynova Announce Strategic Partnership on Accelerating R&D of Small Molecule Innovative Drugs with AI | SHANGHAI, Aug. 5, 2021 /PRNewswire/ -- Insilico Medicine, an industry leader in end-to-end artificial intelligence for target discovery, small molecule chemistry, and clinical development, and Usynova announced to reach strategic cooperatio... |
| 04.08.2021 | Insilico Medicine Announces the Preclinical Candidate for Kidney Fibrosis Discovered Using End-to-End Artificial Intelligence Engine | HONG KONG, Aug. 4, 2021 /PRNewswire/ -- Insilico Medicine, a global company specializing in the applications of the next-generation machine learning technologies for drug discovery and development, announced today that its AI-powered drug d... |
| 23.06.2021 | Insilico Medicine Raises $255 Million in Series C Financing | - |
| 23.06.2021 | Hong Kong-based Insilico Medicine raises $255M | Insilico Medicine, which uses AI to discover and develop drugs, has secured a $255 million Series C led by Warburg Pincus. Investors including Qiming Venture Partners, OrbiMed and Sequoia China also participated. The Hong Kong-based company... |
| 23.06.2021 | Insilico Medicine Raises $255 Million In Series C Financing Led By Warburg Pincus | Insilico Medicine, a global leader in end-to-end artificial intelligence for target discovery, small molecule chemistry, and clinical development, announced that it has closed a $255 million Series C financing led by Warburg Pincus. The fin... |
| 22.06.2021 | The battle forming in the European fintech scene | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox.
It’s no secret: Venture capitalists have grown bullish about Europe.
In the first quarter of the ... |
| 22.06.2021 | Insilico Medicine Raises $255 Million in Series C Financing Led by Warburg Pincus
USA - English USA - English | |
| 22.06.2021 | Insilico Medicine scores $255M venture round to move AI-designed drugs into human clinical trials
Fierce Pharma Webinar | The advent of artificial intelligence holds the promise to reset the industry’s expectations of how long it should take to develop a new drug from scratch. And with serious new investments, Insilico Medicine is looking to make it an everyda... |
| 22.06.2021 | Insilico Medicine Raises $255 Million in Series C Financing Led by Warburg Pincus | NEW YORK and HONG KONG, June 22, 2021 /PRNewswire/ -- Insilico Medicine, a global leader in end-to-end artificial intelligence for target discovery, small molecule chemistry, and clinical development, announced that it has closed a $255 mil... |
| 22.06.2021 | The battle forming in the European fintech scene | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox.
Paid Content The true value of equity compensation From Personal Capital
It’s no secret: Venture ... |
| 22.06.2021 | Tech-enabled drug discovery startup Insilico Medicine lands $225 million | Photo: Kwanchai Lerttanapunyaporn/Getty Images |
| 22.06.2021 | Warburg leads $255m Series C in HK-based AI drug discovery firm Insilico Medicine | Insilico Medicine, a Hong Kong-based firm that uses artificial intelligence (AI) for drug discovery and ageing research, announced on Tuesday that it has raked in $255 million in a Series C round of financing led by US private equity (PE) g... |
| 22.06.2021 | Warburg leads $255m Series C in HK-based AI drug discovery firm Insilico Medicine | Premium
Insilico Medicine, a Hong Kong-based firm that uses artificial intelligence (AI) for drug discovery and ageing research, announced on Tuesday that it has raked in $255 million in a Series C round of financing led by US private equit... |
| 22.06.2021 | AI drug discovery platform Insilico Medicine announces $255 million in Series C funding | Insilico Medicine, an AI-based platform for drug development and discovery, announced $255 million in Series C financing on Tuesday. The massive round is reflective of a recent breakthrough for the company: proof that its AI-based platform ... |
| 22.06.2021 | Insilico Medicine Raises $255M in Series C Financing | Insilico Medicine, a Hong Kong-based global leader in end-to-end artificial intelligence for target discovery, small molecule chemistry, and clinical development, closed a $255m Series C financing.
The round was led by Warburg Pincus with p... |
| 09.03.2021 | UCB
UCB : Insilico's Chemistry42 AI system integrated into UCB's drug discovery programs | HONG KONG, March 9, 2021 /CNW/ -- Insilico Medicine, an AI drug discovery company, announced that UCB will integrate Insilico's Chemistry42™ into UCB's internal drug discovery pipeline. UCB's early adoption of Insilico Medicine's proprietar... |
| 06.02.2020 | Startup uses A.I. to identify molecules that could fight coronavirus | Insilico Medicine, a startup based in Rockville, Md., says it has used artificial intelligence to rapidly identify molecules that could form the basis of an effective treatment against the coronavirus at the heart of the current outbreak.
I... |
| 30.01.2020 | What Living To 150 Might Look Like | We see the headlines every day. “13 Habits Linked to a Long Life (Backed by Science),” “There’s no limit to longevity, says study that revives human lifespan debate,” “Is longevity determined by genetics?” |
| 19.11.2019 | Учёные научили алгоритмы генерировать молекулы против фиброза и других сложных заболеваний — в 63 раза быстрее людей Статьи редакции... | Соавтор исследования и основатель компании Insilico Medicine Александр Жаворонков — об истории открытия, инвестициях и особенностях мировой фарминдустрии.
9 9 комментариев
4672 просмотров
Александр Жаворонков на конференции Pioneers
В сентя... |
| 13.09.2019 | Insilico Medicine Raises $37M in Series B Funding | Insilico Medicine, a Hong Kong-based developer of next-generation artificial intelligence technology for drug discovery, completed a $37m Series B funding round.
The round was led by Qiming Venture Partners, joined by Eight Roads, F-Prime C... |
| 11.09.2019 | China Digest: Qiming leads $37m Series B in Insilico Medicine; IceKredit raises $47m | Premium
Insilico Medicine, an AI-technology drug discovery firm, has raised $37 million in its Series B funding while risk management platform IceKredit secures $47 million in pre-Series C round.
Continue reading this story with a subscript... |
| 10.09.2019 | Insilico Medicine Secures $37M in Series B Funding Led by... | - |
| 10.09.2019 | Insilico Medicine secures $37M in series B funding | - |
| 09.09.2019 | Daily funding roundup - September 9th, 2019 | Drivetime raised $11M; CasperLabs landed $14.5M; Kite Hill closed a $15M
Emi Labs: Emi Labs is a conversational AI platform for HR teams. Emi Labs has raised $2 million in seed funding led by Khosla Ventures. Read more
Uizard: Uizard is a c... |
| 01.07.2019 | Longenesis Brings South Korean Medical Records to the Blockchain | Longenesis, a Riga, Latvia-based but Hong Kong-incorporated company, is bringing medical records to the blockchain in South Korea using Bitfury's Exonum platform.
Longenesis
, which was formed in late 2017, provides a suite of modular block... |
| 19.07.2018 | Consortium.AI wants to cure rare diseases using artificial intelligence | We are excited to bring Transform 2022 back in-person July 19 and virtually July 20 - 28. Join AI and data leaders for insightful talks and exciting networking opportunities. Register today!
Duchenne Muscular Dystrophy (DMD) is a rare muscl... |
| 19.07.2018 | Consortium.AI wants to cure rare diseases using artificial intelligence | Duchenne Muscular Dystrophy (DMD) is a rare muscle disorder affecting children that results in loss of the ability to walk. It’s rapidly progressive — average life expectancy is about 20 years — and caused by genetic mutations on the X chro... |
| 13.06.2018 | Insilico Medicine receives strategic investment from Chinese biotech firm | Baltimore-based Insilico Medicine landed a new strategic investment from Chinese biotech company WuXi AppTec.
The amount of the funding was not disclosed, but the investment also includes a strategic partnership between Insilico and WuXi, w... |
| 12.06.2018 | Insilico Medicine Completes Strategic Funding Round | Insilico Medicine, a Baltimore-based next-generation artificial intelligence company specialized in the application of deep learning for target identification, drug discovery and aging research, completed a strategic round of funding of und... |
| 11.06.2018 | WuXi AppTec Leads Strategic Investment in Insilico Medicine | Insilico Medicine, a Baltimore-based next-generation artificial intelligence company specialized in the application of deep learning for target identification, drug discovery and aging research, announces the completion of a strategic round... |
| 11.06.2018 | With strategic investment, Insilico Medicine is using deep learning to defeat aging | Every once in a while, you meet an entrepreneur who is both fully present, but also has a head full of dreams. That was my experience meeting and hosting Alex Zhavoronkov, the founder and CEO of Insilico Medicine, a few weeks ago in Vienna ... |
| - | How AI turbocharged the development of a new drug and what it might mean for health care | This is Diane Brady, editorial director of the Fortune CEO Initiative, filling in today for Peter Vanham.
As we previously reported in Impact Report, health care is arguably the most exciting and impactful use case for AI. In the past week,... |
| - | Schrödinger: инвестиции в drug discovery и materials science. Есть ли перспективы после падения акций на 70%? | Для инвесторов в биотех и фармацевтические компании последний год выдался непростым. Популярный ETF SPDR S&P Biotech, он же XBI, состоящий в основном из биотехов малой и средней капитализации, потерял уже более 40% с пиковых значений в ... |
| - | UCB : Insilico's Chemistry42 AI system integrated into UCB's drug discovery programs | HONG KONG, March 9, 2021 /CNW/ -- Insilico Medicine, an AI drug discovery company, announced that UCB will integrate Insilico's Chemistry42™ into UCB's internal drug discovery pipeline. UCB's early adoption of Insilico Medicine's proprietar... |
| - | Insilico Medicine Secures $37M in Series B Funding Led by Qiming Venture Partners | - |
| - | Aramco’s VC arm leads $35m round of Hong Kong biotech firm | InvestmentsNewsStartups
Aditya Hadi Pratama · 1d ago · 2 min readAramco’s VC arm leads $35m round of Hong Kong biotech firm
Insilico Medicine, a Hong Kong-based biotechnology firm, has raised US$35 million in a series D2 funding round led b... |
